Hosseinzadeh Ramin, Goharrizi Mohammad Ali Sheikh Beig, Bahardoust Mansour, Alvanegh Akbar Ghorbani, Ataee Mohammad Reza, Bagheri Mehdi, Navidiyan Ensiyeh Shabani, Zijoud Seyed Reza Hosseini, Heiat Mohammad
Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Clin Hypertens. 2021 Jan 15;27(1):3. doi: 10.1186/s40885-021-00161-7.
Hypertension, the most common comorbidity among coronavirus disease 2019 (COVID-19) patients, is accompanied by worse clinical outcomes, but there is lack of evidence about prognostic factors among COVID-19 patients with hypertension. We have come up with some prognostic factors to predict the severity of COVID-19 among hypertensive patients. In addition, epidemiologic, clinical and laboratory differences among COVID-19 patients with and without underlying hypertension were evaluated.
Medical profiles of 598 COVID-19 cases were analyzed. Patients were divided into two comparative groups according to their positive or negative history of hypertension. Then, epidemiologic, clinical, laboratory and radiological features and also clinical outcomes were compared.
176 (29.4%) patients had underlying hypertension. Diabetes was significantly higher in hypertensive group [72 (40.9%) vs 76 (18%)] (P-value: 0.001). Cardiovascular and renal disorders were significantly higher in hypertensive patients. (P-value: 0.001 and 0.013 respectively). In COVID-19 patients with hypertension, severe/critical types were significantly higher. [42(23.8%) vs. 41(9.7%)], (P-value: 0.012). In the logistic regression model, Body mass index > 25 (OR: 1.8, 95% CI: 1.2 to 2.42; P-value: 0.027), age over 60 (OR: 1.26, 95% CI: 1.08 to 1.42; P-value: 0.021), increased hospitalization period (OR: 2.1, 95% CI: 1.24 to 2.97; P-value: 0.013), type 2 diabetes (OR: 2.22, 95% CI: 1.15 to 3.31; P-value: 0.001) and chronic kidney disease (OR: 1.83, 95% CI: 1.19 to 2.21; P-value: 0.013) were related with progression of COVID-19.
Hypertensive patients with Age > 60-year-old, BMI > 25 Kg/m, CVD, diabetes and chronic kidney disease are associated with poor outcomes in those with COVID-19 infection.
高血压是2019冠状病毒病（COVID-19）患者中最常见的合并症，与更差的临床结局相关，但缺乏关于COVID-19高血压患者预后因素的证据。我们提出了一些预后因素来预测高血压患者中COVID-19的严重程度。此外，还评估了有和没有基础高血压的COVID-19患者在流行病学、临床和实验室方面的差异。
分析了598例COVID-19病例的病历。根据患者高血压病史阳性或阴性将其分为两个比较组。然后，比较了流行病学、临床、实验室和放射学特征以及临床结局。
176例（29.4%）患者有基础高血压。高血压组糖尿病患病率显著更高[72例（40.9%）对76例（18%）]（P值：0.001）。高血压患者心血管和肾脏疾病患病率显著更高（P值分别为0.001和0.013）。在COVID-19高血压患者中，重症/危重症类型显著更多[42例（23.8%）对41例（9.7%）]，（P值：0.012）。在逻辑回归模型中，体重指数>25（比值比：1.8，95%置信区间：1.2至2.42；P值：0.027）、年龄超过60岁（比值比：1.26，95%置信区间：1.08至1.42；P值：0.021）、住院时间延长（比值比：2.1，95%置信区间：1.24至2.97；P值：0.013）、2型糖尿病（比值比：2.22，95%置信区间：1.15至3.31；P值：0.
